Cola, Spotify, Starbucks, and more. From missed profits to tariff tensions, here's what investors need to know about the ...

Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' ...

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Pfizer stock inched down Tuesday on a mixed first-quarter report. Sales missed, but cost cutting led to strong earnings.

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...